Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | MC5R | P33032 | 3/20 | 0.48 |
| ▸ | MC4R | P32245 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | MC3R | P41968 | 1/20 | 0.46 |
| ▸ | VDR | P11473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955760 | 1.00 | CYP1A2 (0.56) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL11634757 | 0.93 | CYP1A2 (0.48) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL29058801 | 0.93 | CYP1A2 (0.48) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL27943264 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL30753810 | 0.82 | CYP1A2 (0.47) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL835673 | 0.81 | CYP1A2 (0.51) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL3816833 | 0.81 | ALDH1A1 (0.52) | CYP1A2CYP2A6RAB9AMC5RMAPK1 | |
| SCHEMBL11739548 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP2A6RAB9AMAPK1KMT2A | |
| SCHEMBL4180971 | 0.80 | CYP1A2 (0.54) | CYP1A2CYP2A6RAB9AMC5RMC4R | |
| SCHEMBL7269786 | 0.80 | CYP2A6 (0.59) | CYP1A2CYP2A6RAB9AMC5RMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346753-A1 | PRO-BENEFIT AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS | The Procter & Gamble Company (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4347573-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | The Procter & Gamble Company (US) | 2024-04-10 | — | — | EP | claimed |
| EP-4259286-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | The Procter & Gamble Company (US) | 2023-10-18 | — | — | EP | claimed |
| EP-4251723-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2023-10-04 | — | — | EP | claimed |
| EP-4146778-A1 | FRAGRANCE COMPOSITION | Givaudan SA (CH) | 2023-03-15 | — | — | EP | claimed |
| WO-2022251818-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2022251817-A1 | PRO-BENEFIT AGENT COMPOUNDS WITH CARBON/NITROGEN BONDS | THE PROCTER & GAMBLE COMPANY (US) | 2022-12-01 | — | — | WO | claimed |
| WO-2022130403-A1 | NEW QUATERNARY AMMONIUM SALTS FOR TRIFLUOROMETHYLATION AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2022-06-23 | — | — | WO | claimed |
| WO-2022126093-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2022112202-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2022-06-02 | — | — | WO | claimed |
| EP-1922398-A1 | CONSUMER PRODUCTS HAVING VARYING ODOR PATTERNS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-05-21 | — | — | EP | claimed |
| WO-2007028477-A1 | CONSUMER PRODUCTS HAVING VARYING ODOR PATTERNS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | claimed |
| WO-2007028479-A1 | CONSUMER PRODUCTS HAVING VARYING ODORS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-03-15 | — | — | WO | claimed |
| EP-1113105-B1 | Human sweat malodor counteractant composition and process for using same | INT FLAVORS & FRAGRANCES INC (US) | 2006-04-05 | — | — | EP | claimed |
| EP-1082287-B1 | SLOW RELEASE OF FRAGRANT COMPOUNDS IN PERFUMERY USING 2-BENZOYL BENZOATES, 2-ALKANOYL BENZOATES OR ALPHA-KETO ESTERS | FIRMENICH & CIE (CH) | 2004-03-17 | — | — | EP | claimed |
| US-6492323-B2 | CONTROLLED RELEASE UPON EXPOSURE TO LIGHT | FIRMENICH SA (CH) | 2002-12-10 | — | — | US | claimed |
| US-20010014661-A1 | Slow release of fragrant compounds in perfumery using alpha-keto esters | FIRMENICH SA (CH) | 2001-08-16 | — | — | US | claimed |
| US-6218355-B1 | FOR RELEASING FRAGRANT COMPOUND OR COMPOUNDS IN A CONTROLLED MANNER, MAINTAINING A DESIRED SMELL OVER A PROLONGED PERIOD OF TIME | FIRMENICH SA (CH) | 2001-04-17 | — | — | US | claimed |
| EP-1082287-A2 | SLOW RELEASE OF FRAGRANT COMPOUNDS IN PERFUMERY USING 2-BENZOYL BENZOATES, 2-ALKANOYL BENZOATES OR ALPHA-KETO ESTERS | FIRMENICH SA (CH) | 2001-03-14 | — | — | EP | claimed |
| WO-1999060990-A2 | SLOW RELEASE OF FRAGRANT COMPOUNDS IN PERFUMERY USING 2-BENZOYL BENZOATES, 2-ALKANOYL BENZOATES OR α-KETO ESTERS | FIRMENICH S.A. (CH) | 1999-12-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014661-A1 | Slow release of fragrant compounds in perfumery using alpha-keto esters | FAAH, KHK, FAAH2 | CYP1A2 258/4885CYP2A6 280/4885RAB9A 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.